GSK-4069327A is under clinical development by LimmaTech Biologics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GSK-4069327A’s likelihood of approval (LoA) and phase transition for Bacillary Dysentery (Shigellosis) took place on 08 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GSK-4069327A Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GSK-4069327A overview

GSK-4069327A (GVXN-SD133) is under development for the prophylaxis for Shigella diarrhoea caused by Shigella dysenteriae. It is a biconjugate tetravalent vaccine. The vaccine candidate is administered intramuscularly. GVXN SD133 vaccine is developed based on bioconjugate vaccine technology.

LimmaTech Biologics overview

LimmaTech Biologics is a clinical-stage biopharmaceutical company focused on the development and manufacturing of novel therapeutic proteins or bioactive molecules. The company conducts clinical trials on shigella bacteria to help prevent diarrheal diseases and Klebsiella studies to prevent klebsiella infections. LimmaTech Biologics‘ proprietary bioconjugation platform also enables the research and development of innovative vaccines for a wide range of disease indications. The company specializes in vivo carbohydrate engineering to develop drugs for both the treatment and prevention of life-threatening diseases. It seeks to work in partnership with other pharmaceutical companies for research and development of bioconjugates as vaccines. LimmaTech Biologics is headquartered in Zurich, Switzerland.

Quick View GSK-4069327A LOA Data

Report Segments
  • Innovator
Drug Name
  • GSK-4069327A
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.